AVP-21D9

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
AVP-21D9

GtoPdb Ligand ID: 13720

Synonyms: Thravixa®

Compound class: Antibody

Comment: AVP-21D9 is a fully human IgG1 monoclonal antibody that targets the protective antigen (PA) component of Bacillus anthracis toxin [1-2]. It is being developed as an intravenous treatment for anthrax following exposure to B. anthracis.

Summary
Biological activity
Clinical data
References

Bioactivity Comments
The therapeutic efficacy of AVP-21D9 has been evaluated in animal models of inhalational anthrax, with survival of up to 92% of rabbits and 67% of cynomolgus macaques infected with B. anthracis [1].

Bioactivity Comments

The therapeutic efficacy of AVP-21D9 has been evaluated in animal models of inhalational anthrax, with survival of up to 92% of rabbits and 67% of cynomolgus macaques infected with B. anthracis [1].